tbuckley/cabot-search huggingface dataset:
Prognostic factors for long-term survival in ICU tracheostomized patients
Authors: Damien Basille, Eline Magois, Claire Andrejak, Vincent Jounieaux
Journal: European Respiratory Journal (2011)

Introduction:  Few recent studies have evaluated the long-term prognosis of ICU patients who are tracheostomized for their underlying lung disease.   Patients and methods:  We conducted a retrospective study from 1997 to 2010 in 82 patients who were tracheostomized during their stay in a medical intensive care unit (ICU). The main objective was the evaluation of long-term survival   Results:  Among the 82 patients, 40 (48.8%) have a chronic respiratory failure (16 obstructive, 9 mixed and 15 restrictive with 11 neuromuscular disease). Fifty-nine patients (72%) died, including 32 (39%) before hospital discharge. The median survival time is 188 days. In multivariate analysis using the Cox model, three prognostic factors have been highlighted: 1) the presence of a neurological disease was significantly associated with a better prognosis (OR 0.48 [0.26-0.9], p = 0.022), 2) an age above 65 years (OR = 2.2 [1.17-4.16], p = 0.015) and 3) a Charlson score greater than 2 (OR = 2.05 [1.09-3.86] p = 0.026) were significantly associated with a poor prognosis. GOLD stage IV COPD was not associated with a poor prognosis (OR = 1.93 [0.98-3.81], p = 0.058). Bleeding or respiratory complications were found respectively in 16 (20%) and 7 (9%) patients. Among patients discharged from hospital, the weaning of mechanical ventilation was obtained in 19 of 46 cases (41.3%).   Conclusion:  We found two pejorative prognostic factors (age > 65 years and a Charlson score > 2) and one protective factor (presence of a neurological disease) significantly related to the long-term survival in ICU tracheostomized patients.
Nitrogen dioxide is linked to 5900 deaths a year in London, report says
Authors: Jacqui Wise
Journal: BMJ (2015)

Nitrogen dioxide is associated with nearly 5900 deaths a year in London, concludes a report that assessed the effects on health of the city’s air pollutants.1

The research, carried out by King’s College London and commissioned by the Greater London Authority and Transport for London, found that in 2010, the most recent year with available data, the total mortality burden of long term exposure to nitrogen dioxide was an estimated 88 113 life years lost, equivalent to 5879 premature deaths across London. The gas is largely created by diesel engines in cars, lorries, and buses.

However, the report did point out that emerging techniques had been used to assess the mortality burden of nitrogen dioxide and that the figures …
Lower risk of suicide during pregnancy
Authors: P M Marzuk, K Tardiff, A C Leon, C S Hirsch, L Portera, N Hartwell, M I Iqbal
Journal: American Journal of Psychiatry (1997)

The authors determined the risk of suicide during pregnancy.The autopsy reports of all female residents of New York City, 10-44 years old, who committed suicide from 1990 to 1993 were assessed for pregnancy. These data were compared with age-adjusted and race-adjusted standardized mortality ratios for women, which were calculated by using population data from the 1990 U.S. Census as well as data obtained from the New York City Health Department on the number of live births, spontaneous abortions, and induced abortions.The standardized mortality ratio for suicide during pregnancy was 0.33; that is, the number of suicides of pregnant women was only one-third of that expected.Despite the mood swings and stresses associated with pregnancy and impending childbirth, pregnant women have a significantly lower risk of suicide than women of childbearing age who are not pregnant.
Randomized pilot trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer: preliminary data
Authors: V. M. Chung, C. Ruel, M. Cristea, T. H. Luu, L. Leong, M. McNamara, C. Martel, D. Lim, P. Twardowski, R. J. Morgan
Journal: Journal of Clinical Oncology (2008)

16555 Background: The increased tumorigenic potential of COX-2 overexpressing cells is thought to be mediated in part by resistance to apoptosis, and treatment with selective COX-2 inhibitors has been shown to induce apoptosis in a variety of cancer cells. Single agent cyclophosphamide (CTX) has known activity against ovarian cancer and the combination of celecoxib with daily oral CTX will exploit the possibility of synergistic antiangiogenic and anti-tumor activity of these compounds without apparent overlapping toxicities. Methods: Patients (pts) were randomized to one of two treatment arms. Arm A consists of oral CTX 50 mg daily (1 cycle = 4 weeks) and Arm B consists of oral CTX 50 mg daily and celecoxib 400 mg twice daily. Simon’s Two-Stage minimax Phase II design was used for each arm. Provided that one or more responses was observed in the first 13 evaluable pts, continuation of that arm will continue, and an additional 14 evaluable pts will be accrued to that arm during the second stage of accrual. Results: A total of 29 pts have been accrued with 14 pts in Arm A and 15 pts in Arm B. The median age was 65 (range 34–79) in Arm A and 60 (range 48–78) in Arm B. KPS ranged from 70–100 in Arm A and 80–100 in Arm B. Arm A had a best response of stable disease in 3 pts while Arm B had 1 pt with a partial response and 5 with stable disease. There were no grade 4 toxicities attributable to treatment. The grade 3 toxicities in Arm A attributable to treatment were weakness in 2 pts, neuropathy in 2 pts, neutropenia in 1 pt, dyspnea in 1 pt, fatigue in 1 pt and elevated AST in 1 pt. Arm B had 1 pt with grade 3 dyspepsia and 1 pt with rash. One pt randomized to Arm B was taken off treatment due to an allergic reaction to celecoxib and was treated off study with oral cyclophosphamide. Her CA125 decreased from 1030 to 19.3 and she has had stable disease for over 1 year. Conclusions: Low dose daily CTX with or without celecoxib is well tolerated and has activity in ovarian cancer. No significant financial relationships to disclose.
Inhibition of Replication of the Etiologic Agent of Acquired Immune Deficiency Syndrome (Human T-Lymphotropic Retrovirus/Lymphadenopathy-Associated Virus) by Avarol and Avarone&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: P S Sarin, D Sun, A Thornton, W E Müller
Journal: JNCI Journal of the National Cancer Institute (1987)

Avarol and avarone are two antimitotic and antimutagenic agents that preferentially inhibit proliferation of T-cell leukemia lines in vitro. This report shows that these compounds have a dose-dependent inhibitory effect on the replication of the etiologic agent of acquired immune deficiency syndrome (AIDS), human T-lymphotropic retrovirus (HTLV-III)/lymphadenopathy-associated virus, in human H9 cells in vitro. Both compounds show a significant cytoprotective effect on HTLV-IIIB-infected H9 cells at concentrations as low as 0.1 microgram/ml (0.3 microM). Both avarone and avarol block in a dose-dependent manner the expression of the p24 and p17 gag proteins of HTLV-III in H9 cells after virus infection and block viral replication, as judged by approximately 80% inhibition of reverse transcriptase activity. These results strongly suggest that these compounds may prove to be useful in the treatment of patients with AIDS and AIDS-related complex.
Glutamine for Irinotecan Diarrhea
Authors: Diane Savarese, Ammar Al-Zoubi, Jean Boucher
Journal: Journal of Clinical Oncology (2000)

Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2000.18.2.450 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 10637264 Glutamine for Irinotecan Diarrhea Diane SavaresexDiane SavareseSearch for articles by this author , Ammar Al-ZoubixAmmar Al-ZoubiSearch for articles by this author , Jean BoucherxJean BoucherSearch for articles by this author Show More UMass Memorial Health Care WorcesterMA https://doi.org/10.1200/JCO.2000.18.2.450 First Page Full Text PDF Figures and Tables © 2000 by American Society of Clinical Oncology
Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2
Authors: R. Lilenbaum, R. Axerold, S. Thomas, A. Dowlati, L. Seigel, D. Albert, C. Van Duym, D. Bodkin
Journal: Journal of Clinical Oncology (2006)

7022 Background: A previous CALGB trial suggested a benefit for carboplatin-paclitaxel (CP) over P alone in pts with PS 2. Erlotinib (E) has activity in previously treated pts with low PS but has not been formally tested in 1st line. Methods: In a multi-center randomized phase II trial, untreated pts with advanced NSCLC and PS 2 were randomized to E 150 mg daily or CP (AUC 6 and 200 mg/m 2 ) for 4 cycles. Pts in CP who progressed, did not tolerate, or refused further therapy were allowed to cross over to E. The primary endpoint was progression-free survival (PFS). QoL analysis was performed in all pts and tumor samples were obtained whenever possible. Results: As of 12/05, 98 of 102 projected pts have been accrued. Results are reported for 88 (46 E; 42 CP). Demographics were balanced except for more females in E (59%) than CP (45%). Most pts had stage IV adenoca histology. Never-smokers comprised 13% and 7% of pts respectively. Response for E: 2% PR and 30% SD; for CP, 10% PR and 45% SD. Gr 2–4 toxicities for E: rash (34%) and diarrhea (11%); for CP: nausea (12%), neuropathy (14%) and fatigue (29%). Median PFS was 2.5 mo for E (95%CI 1.28 - 2.79) and 4.0 mo for CP (95%CI 2.66 - 4.86). Of 42 pts in CP, 21 have crossed over to E. Conclusions: This is the first randomized phase II trial of E in PS 2 patients. Based on preliminary results, PS 2 patients seemed to fare better with standard CP than single agent E as initial therapy. Mature survival and QoL data will be available in June. [Table: see text]
Vancomycin resistant enterococci (VRE) infections in hematopoietic stem cell transplant (HSCT) recipients
Authors: A. E. Rosko, L. M. Arfons, P. M. Barr, B. W. Cooper, T. Kindwall-Keller, M. J. Laughlin, S. Gerson, R. J. Creger, P. Fu, M. R. Jacobs, H. M. Lazarus
Journal: Journal of Clinical Oncology (2009)

7036 Background: VRE blood stream infections (BSI) pose significant hazards to HSCT patients. Risk factors predisposing patients for a relatively nonpathogenic organism to become bacteremic include immune suppression, neutropenia, renal failure, antibiotic exposure, indwelling catheters, and VRE colonization. Some studies suggest that a VRE BSI is simply a marker of primary disease severity or an indicator of poor outcome, while other data demonstrate VRE BSI as an independent predictor of mortality. Methods: We performed a retrospective chart analysis of HSCT patient data using the electronic medical record and written charts using a standard data collection tool from February 1994 to October 2008. Vancomycin susceptibility was determined using the Dade Berhing panel. Results: We noted 625 infections in 385 HSCT patients; 26 patients developed 27 VRE infections over the course of 15 years. All isolates were Enterococcus faecium and not polymicrobial. Host characteristics included mean age of 49.5 yrs, all had central venous catheters, and 26 received linezolid treatment. Persistent infection was identified in 11 patients with central access removal in 4. VRE colonization was identified in stool (18 patients) and urine (5 patients) and 4 patients had a prior VSE BSI. 16 patients received vancomycin within 30 days of developing VRE BSI. 21 patients were neutropenic (mean duration15 days). 8 patients were not receiving immunosuppressants during time of bacteremia. Gastrointestinal endoscopy was identified in 6 patients prior to BSI. 16 patients died during the hospitalization. Conclusions: VRE accounted directly or indirectly for 13 of 16 deaths during incident hospitalization. In this population, blood, urine, stool surveillance is warranted to prevent morbidity/mortality related to developing a VRE BSI. Prolonged neutropenia was associated with development of a VRE BSI prophylactic granulocyte transfusion might be useful to prevent BSI. In contrast to prior studies, many patients were not receiving immunosuppressants and did not undergo GI instrumentation. VRE BSI prevention should include identifying patients with urinary or stool colonization, appropriate isolation and early central venous catheter removal if a VRE BSI is identified. No significant financial relationships to disclose.
The cyclin kinase inhibitor p21WAF1, CIP1 is increased in experimental diabetic nephropathy
Authors: C J Kuan, M al-Douahji, S J Shankland
Journal: Journal of the American Society of Nephrology (1998)

High glucose inhibits mesangial cell proliferation in vitro and induces hypertrophy in mesangial cells in culture and in experimental diabetic nephropathy. Cell growth is ultimately controlled at the level of the cell cycle by cell cycle regulatory proteins. Cell cycle progression requires that cyclin-dependent kinases be activated by cyclins. Cyclin kinase inhibitors (CKI) inactivate cyclin-dependent kinases, causing cell cycle arrest. In the current study, high glucose-induced mesangial cell hypertrophy in vitro is shown to be associated with increased levels of the CKI p21, but not p27. In the streptozotocin model of experimental diabetes in the mouse, glomerular hypertrophy was associated with a selective increase in p21 expression, whereas the levels of the CKI p27 and p57 did not change. Unlike many other forms of glomerular injury, diabetic nephropathy was not associated with increased apoptosis. These results support a role for p21 in causing glomerular cell hypertrophy in diabetic nephropathy.
Leiomyosarcoma of the urinary bladder after cyclophosphamide.
Authors: J Pedersen-Bjergaard, V Jønsson, M Pedersen, K Hou-Jensen
Journal: Journal of Clinical Oncology (1995)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1995.13.2.532 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7844616 Leiomyosarcoma of the urinary bladder after cyclophosphamide. J Pedersen-BjergaardxJ Pedersen-BjergaardSearch for articles by this author , V JønssonxV JønssonSearch for articles by this author , M PedersenxM PedersenSearch for articles by this author , K Hou-JensenxK Hou-JensenSearch for articles by this author https://doi.org/10.1200/JCO.1995.13.2.532 PDF "Leiomyosarcoma of the urinary bladder after cyclophosphamide.." Journal of Clinical Oncology, 13(2), pp. 532–533© 1995 by American Society of Clinical Oncology
Association of multiple pulmonary metastases with response to gefitinib in patients with non-small cell lung cancer
Authors: K. Goto, E. Kim, K. Kubota, S. Niho, R. Kakinuma, H. Ohmatsu, K. Yoh, K. Nagai, Y. Nishiwaki
Journal: Journal of Clinical Oncology (2004)

7098 Background: Gefitinib, an oral selective inhibitor of the epidermal growth factor receptor tyrosine kinase, has been shown to exhibit excellent antitumor activity against non-small cell lung cancer. To identify the unique clinical characteristics of sensitive patients to gefitinib, retrospective analysis was conducted. Methods: From June 2002 to October 2003, total 252 patients received gefitinib in our institute, and 222 patients were eligible for this analysis. Median age was 64 years, and 141 patients (64%) were male. Histological type was adenocarcinoma in 166 patients (75%). One hundred sixty-nine patients (76%) received previous chemotherapy. Seventy patients (32%) had multiple pulmonary metastases that was defined as detecting more than 6 of pulmonary nodules in the bilateral lung on conventional computed tomography of the chest. Results:There were 60 partial responses for an overall response rate of 27%. Female patients (44%), never smoker (56%), adenocarcinoma (34%), and multiple pulmonary metastases (51%) had relatively high response rate, and they were significantly associated with gefitinib response by univariate analysis. In particular, 18 adenocarcinomas with diffuse miliary pulmonary metastases in the bilateral lung showed high response rate (67%). Multivariate analysis showed that multiple pulmonary metastases (p<0.0001) and never smoker (p<0.0001) were significantly associated with clinical response to gefitinib. Thirty-five non-smoker patients of lung adenocarcinoma with multiple pulmonary metastases were included in this study, and they showed 74% of response rate. Conclusions: Non-smoker and patient with multiple pulmonary metastases, in particular diffuse miliary metastases, were significantly associated with the response to gefitinib. No significant financial relationships to disclose.
Survivorship care planning needs in diffuse large B-cell lymphoma (DLBCL)
Authors: D. R. Friedman, A. H. Dupont, A. D. Coan, J. E. Herndon, K. L. Rowe, A. P. Abernethy
Journal: Journal of Clinical Oncology (2009)

e20703 Background: Cancer survivorship care plans inform and direct care in the survivorship setting. These care plans should be tailored to individual medical information, needs, and circumstances, as providing excess information can be overwhelming. According to survivors of DLBCL, what are important components of care plans? Methods: We developed a 22-question survey to define and rate important survivorship health and psychosocial concerns; items were developed based upon literature review and experience in survivorship clinics. Through the tumor registry, 178 patients were identified who had been treated with curative intent (including stem cell transplant) without evidence of recurrence since 1/2006 and who continue to receive care at Duke University Medical Center. Results: Sixty-five survivors consented and returned a completed IRB approved survey (response rate 37%). Responders: 58% female, 88% white, and 75% from North Carolina, with mean age at diagnosis of 59.7 years; 42% had stage four disease at diagnosis and 12% had had a transplant. The majority of survey participants (62%) indicated that they preferred their oncologist and primary care provider to jointly manage their survivorship care. On a 1–10 scale, the top scoring issue (mean 9.67) was “A plan to screen for possible return of your cancer.” Other top scoring issues (mean 8.81 - 9.48) related to cancer history (treatment, complications, stage or late effects) and non-cancer health monitoring. The lowest scoring needs related to social support, sexuality, financial/legal issues, alternative medicine, and mental health services (mean 5.45 - 7.12). There was greater agreement among responders on the importance ratings of the higher scoring issues than the lower scoring ones (standard deviation 1.01 - 2.34 vs. 3.18 - 3.56). Conclusions: DLBCL survivors prefer care plans focused on medical issues, and health care coordinated jointly by oncologists and primary care physicians. The lower importance of psychosocial issues and alternative medicine in this population differs from survivors of other cancers, underscoring the importance of tailoring care plans by cancer subgroup. No significant financial relationships to disclose.
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer
Authors: Andrew G. Nicholson, Kari Chansky, John Crowley, Ricardo Beyruti, Kaoru Kubota, Andrew Turrisi, Wilfried E.E. Eberhardt, Jan van Meerbeeck, Ramón Rami-Porta, Peter Goldstraw, Ramón Rami-Porta, Hisao Asamura, David Ball, David G. Beer, Ricardo Beyruti, Vanessa Bolejack, Kari Chansky, John Crowley, Frank Detterbeck, Wilfried Ernst Erich Eberhardt, John Edwards, Françoise Galateau-Sallé, Dorothy Giroux, Fergus Gleeson, Patti Groome, James Huang, Catherine Kennedy, Jhingook Kim, Young Tae Kim, Laura Kingsbury, Haruhiko Kondo, Mark Krasnik, Kaoru Kubota, Toni Lerut, Gustavo Lyons, Mirella Marino, Edith M. Marom, Jan van Meerbeeck, Alan Mitchell, Takashi Nakano, Andrew G. Nicholson, Anna Nowak, Michael Peake, Thomas Rice, Kenneth Rosenzweig, Enrico Ruffini, Valerie Rusch, Nagahiro Saijo, Paul Van Schil, Jean-Paul Sculier, Lynn Shemanski, Kelly Stratton, Kenji Suzuki, Yuji Tachimori, Charles F. Thomas, William Travis, Ming S. Tsao, Andrew Turrisi, Johan Vansteenkiste, Hirokazu Watanabe, Yi-Long Wu, Paul Baas, Jeremy Erasmus, Seiki Hasegawa, Kouki Inai, Kemp Kernstine, Hedy Kindler, Lee Krug, Kristiaan Nackaerts, Harvey Pass, David Rice, Conrad Falkson, Pier Luigi Filosso, Giuseppe Giaccone, Kazuya Kondo, Marco Lucchi, Meinoshin Okumura, Eugene Blackstone, F. Abad Cavaco, E. Ansótegui Barrera, J. Abal Arca, I. Parente Lamelas, A. Arnau Obrer, R. Guijarro Jorge, D. Ball, G.K. Bascom, A.I. Blanco Orozco, M.A. González Castro, M.G. Blum, D. Chimondeguy, V. Cvijanovic, S. Defranchi, B. de Olaiz Navarro, I. Escobar Campuzano, I. Macía Vidueira, E. Fernández Araujo, F. Andreo García, K.M. Fong, G. Francisco Corral, S. Cerezo González, J. Freixinet Gilart, L. García Arangüena, S. García Barajas, P. Girard, T. Goksel, M.T. González Budiño, G. González Casaurrán, J.A. Gullón Blanco, J. Hernández Hernández, H. Hernández Rodríguez, J. Herrero Collantes, M. Iglesias Heras, J.M. Izquierdo Elena, E. Jakobsen, S. Kostas, P. León Atance, A. Núñez Ares, M. Liao, M. Losanovscky, G. Lyons, R. Magaroles, L. De Esteban Júlvez, M. Mariñán Gorospe, B. McCaughan, C. Kennedy, R. Melchor Íñiguez, L. Miravet Sorribes, S. Naranjo Gozalo, C. Álvarez de Arriba, M. Núñez Delgado, J. Padilla Alarcón, J.C. Peñalver Cuesta, J.S. Park, H. Pass, M.J. Pavón Fernández, M. Rosenberg, V. Rusch, J. Sánchez de Cos Escuín, A. Saura Vinuesa, M. Serra Mitjans, T.E. Strand, D. Subotic, S. Swisher, R. Terra, C. Thomas, K. Tournoy, P. Van Schil, M. Velasquez, Y.L. Wu, K. Yokoi
Journal: Journal of Thoracic Oncology (2015)
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
Authors: Scott Antonia, Sarah B Goldberg, Ani Balmanoukian, Jamie E Chaft, Rachel E Sanborn, Ashok Gupta, Rajesh Narwal, Keith Steele, Yu Gu, Joyson J Karakunnel, Naiyer A Rizvi
Journal: The Lancet Oncology (2016)